There is no commercial support for this activity.

About these speakers

Dr. Patrick B. McGrath serves as the Chief Clinical Officer for NOCD, an app-based platform for the treatment of OCD, leading their teletherapy services across the world. He is also a Lead Psychologist at Ascension Illinois Alexian Brothers Behavioral Health Hospital, where he opened Intensive Outpatient, Partial Hospital, and Residential Treatment Programs for Anxiety Disorders, School Refusal, and OCD. He is also a member of the Scientific and Clinical Advisory Boards of the International OCD Foundation. He is a Fellow of the Association for Behavioral and Cognitive Therapies, and the Past-President of OCD Midwest. He authored “Don’t Try Harder, Try Different,” and “The OCD Answer Book.” He was also featured on Discovery Health Channel’s, “Panic” and on three episodes of TLC’s, “Hoarding; Buried Alive.”

Rachel A. Davis, MD is associate professor of psychiatry with a secondary appointment in neurosurgery at the University of Colorado Anschutz School of Medicine, where she serves as Vice Chair for Clinical Affairs in the Department of Psychiatry.  Dr. Davis is Medical Director of the OCD Program, Co-Director of the OCD Surgical Program, and Director of the Psychiatric Neuromodulation and Advanced Therapeutics Service.  She specializes in treating individuals with severe and refractory OCD, and CU Anschutz/UCHealth is one of just a few academic centers in the world providing deep brain stimulation (DBS) for OCD.  Dr. Davis is interested in the use of DBS for other severe and refractory psychiatric illnesses and is a Principal Investigator on a National Institutes of Health BRAIN initiative, studying the ethics of DBS in schizophrenia.  

Elizabeth Fenstermacher, MD is an assistant professor of psychiatry at the University of Colorado Anschutz School of Medicine, where she serves as the Medical Director of the Transcranial Magnetic Stimulation Service in the Department of Psychiatry.  She also has an appointment through Children’s Hospital Colorado where she is integrated into the neurology department including multidisciplinary clinics treating patients with non-epileptic seizures, functional neurological disorders, and tics and tourette’s disorder.  She specializes in treating children and adolescents with complex psychiatric and neurologic comorbidities, as well as treating adults with treatment refractory depression and obsessive compulsive disorder with TMS.  She is also involved in several neuromodulation initiatives through the University of Colorado in particular several ongoing studies focused on the use of Deep Brain Stimulation for the treatment of severe psychiatric illness (OCD, Depression, Schizophrenia).  Dr. Fenstermacher is interested in translating advances in our understanding of the neurobiology of psychiatric disorders to clinical practice and has developed and taught several neuroscience and genetics courses at different institutions including Brigham and Women’s Hospital, Cambridge Health Alliance, and Children’s Hospital Colorado as well as taught nationally and continues to contribute actively to the curricula of the National Neuroscience Curriculum Initiative where she is a Brain Trust Fellow.

Disclosure Statements

Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she has with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.

Patrick B. McGrath, PhD, & Elizabeth Fenstermacher, MD, reports that they have no relationships with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months. They will not discuss any products, services, or off-label uses in this presentation.

Rachel A. Davis, MD, reports that she is a consultant for Medtronic, Inc. She will also be discussing commercial products with FDA approval for OCD. She will be discussing off-label pharmaceuticals. The content of her presentation has been reviewed to ensure that the information presented is balanced and evidence based.

Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months: Jon Hershfield, MFT, Todd Peters, MD, Deepak Prabhakar, MD, Elizabeth Ryznar, MD, MSc., Louis Marino, MD, Ehsan Syed, MD, Devi Bhuyan, PhD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, Tom Flis, LCPC, Stacey Garnett, RN, MSN, Octavia Coit, MN, Heather Billings, RN, Lisa Illum, MLIS, MEd, and Jennifer Tornabene.